Pharmacogenomics and Antidepressants
Can your genetics help guide the right treatment?
One of the most frustrating experiences in mental health care is this:
you try an antidepressant, feel worse, stop it, try another, and repeat the cycle.
For some people, this process is relatively smooth. For others, it is marked by side effects, minimal benefit, and a growing sense that their body simply doesn’t tolerate medication well.
This is where pharmacogenomics offers a different lens. It asks a simple but powerful question:
What if your response to medication is, in part, written in your genes?
What is pharmacogenomics?
Pharmacogenomics is the study of how genetic variation affects an individual’s response to medications.
When it comes to antidepressants, the focus is largely on genes that influence:
Drug metabolism (how quickly your body processes medication)
Drug transport (how medication moves in and out of the brain)
Drug targets (how medication interacts with receptors)
The most clinically relevant genes for antidepressants are part of the cytochrome P450 enzyme system, particularly:
CYP2D6
CYP2C19
These enzymes determine how quickly many antidepressants are broken down.
Why this matters: fast vs slow metabolisers
We don’t all process medication in the same way.
Based on genetic variation, individuals are broadly classified as:
Poor metabolisers → process drugs slowly → higher drug levels → increased side effects
Intermediate metabolisers → somewhat reduced metabolism
Extensive (normal) metabolisers → expected response
Ultra-rapid metabolisers → process drugs quickly → lower drug levels → reduced effectiveness
This is not theoretical. It has clear clinical implications.
For example:
A CYP2D6 poor metaboliser taking paroxetine or fluoxetine may experience more side effects at standard doses
A CYP2C19 ultra-rapid metaboliser taking citalopram or escitalopram may experience little benefit, as the drug is cleared too quickly
Guidelines from the Clinical Pharmacogenetics Implementation Consortium provide dose adjustments and drug recommendations based on genotype, particularly for SSRIs and tricyclic antidepressants.
What does the evidence show?
Pharmacogenomics is often marketed as a solution to trial-and-error prescribing. The reality is more nuanced.
1. Strong evidence for pharmacokinetics (drug levels)
There is robust evidence that genetic variation in CYP enzymes:
Alters plasma drug concentrations
Influences side effect risk
Affects tolerability
This is why CPIC and the Dutch Pharmacogenetics Working Group both provide actionable prescribing guidance.
2. Moderate evidence for clinical outcomes
Large trials have explored whether pharmacogenomic-guided prescribing improves outcomes in depression.
The GUIDED trial (n≈1,100) found:
Higher response and remission rates in the pharmacogenomics-guided group
The effect size was modest but clinically meaningful
A 2022 meta-analysis found that pharmacogenomic-guided treatment was associated with:
Increased remission rates
Improved response compared to usual care
However, results across studies are heterogeneous, and benefits are not universal.
3. Limited evidence for predicting “which drug will work”
This is the key limitation.
Pharmacogenomics is better at predicting tolerability than efficacy.
In other words, it can often help answer:
“Why did I feel awful on that medication?”
More reliably than:
“Which antidepressant will definitely work for me?”
Where pharmacogenomics is most helpful
In clinical practice, pharmacogenomic testing tends to be most useful in specific scenarios:
1. Multiple medication intolerance
Patients who say:
“I react badly to everything”
This often reflects a combination of:
Genetic differences in metabolism
Heightened physiological sensitivity
Possible nocebo effects
Pharmacogenomics can help separate pharmacological intolerance from sensitivity-driven responses.
2. Unusual or severe side effects at low doses
This raises suspicion of poor metabolism, leading to higher-than-expected drug levels.
3. Lack of response despite adequate dosing
Particularly in ultra-rapid metabolisers, where drug levels may never reach therapeutic range.
4. Complex polypharmacy
When multiple medications interact via CYP pathways, genetic insight can help reduce risk.
What pharmacogenomics does NOT do
It is important to be clear about limitations, especially given the commercialisation of testing.
Pharmacogenomics does not:
Guarantee a “perfect” antidepressant match
Replace clinical judgement
Account for psychological, hormonal, or environmental factors
Fully predict response in conditions like PMDD or trauma-related mood disorders
Mental health is not determined by a single pathway. It is a whole-system process.
The interaction with sensitivity and the nocebo effect
For many patients, particularly those with:
PMDD
Anxiety disorders
Trauma history
High interoceptive sensitivity
Medication response is shaped by more than metabolism alone.
This is where pharmacogenomics needs to be integrated into a broader model.
A patient may be:
A normal metaboliser genetically
But still experience significant side effects due to nervous system sensitivity or expectation effects
Conversely:
A poor metaboliser may experience genuinely higher drug exposure and side effects
Understanding this distinction is powerful.
It allows us to say:
“Some of your response may be pharmacological. Some may be how your nervous system is processing the experience. Both are real, and both can be addressed.”
Practical considerations in the UK
Pharmacogenomic testing is not yet routine in NHS primary care, but is increasingly available privately.
Tests typically involve:
A saliva or cheek swab
Analysis of key pharmacogenes
A report categorising medications into:
Use as directed
Use with caution
Consider alternatives
However, interpretation is key. Raw reports can be misleading without clinical context. Myogenes is a private company that can offer psychiatric pharmacogenomics testing at home, but you will need to have been referred by a clinician
A balanced, personalised approach
At its best, pharmacogenomics supports:
More informed prescribing
Reduced trial-and-error
Improved patient confidence
Better conversations about previous medication experiences
But it works best when integrated with:
Careful clinical history
Understanding of hormonal influences
Awareness of nervous system sensitivity
A strong therapeutic relationship
A more compassionate narrative
If you’ve struggled with antidepressants, it is easy to internalise this as:
“Medication just doesn’t work for me”
or
“I’m too sensitive”
Pharmacogenomics offers a different perspective:
Your response may be biologically influenced, not a personal failing.
And importantly:
Even when genetics play a role, they are only one piece of the picture.
How this fits into care at Sirona Health
In practice, pharmacogenomics is considered as part of a whole-person approach:
Used selectively where it adds value
Interpreted alongside hormonal and psychological factors
Supporting gentle, individualised prescribing strategies
Reducing fear and uncertainty around medication
Because the goal is not just to prescribe a drug.
It is to find an approach your body can work with, not against.
FAQ
-
Not necessarily. It is most helpful in those with previous difficulties, unusual responses, or multiple treatment failures.
-
No. It provides guidance on metabolism and tolerability, but cannot fully predict effectiveness.
-
Often, yes. It can help explain past experiences and guide future choices.
-
It can reduce it, but not eliminate it entirely.